Condition

Triple Negative Breast Cancer clinical trials and research

• 142Clinical trials
• 244NIH research projects
• 2New in 30 days
• 42Countries

Newest Triple Negative Breast Cancer clinical trials

All recruiting trials (142)

• Pre-Treatment Breast DCE-MRI AI Model to Predict Benefit from Neoadjuvant Chemo in Locally Advanced Triple-Negative Breast Cancer

  This study tests an AI model using pre-treatment breast MRI to see if it can identify which locally advanced triple-negative breast cancer patients will benefit most from neoadjuvant chemotherapy.

  Recruiting Fujian Cancer Hospital · Fuzhou, Fujian and 4 other locations · NCT07880600

• JS212-based therapy for recurrent/metastatic TNBC: as monotherapy or with partners

  This phase 2 study tests JS212 alone or with JS207 or JS001 to see if it helps people with recurrent or metastatic triple-negative breast cancer.

  Recruiting Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality and 30 other locations · NCT07876557

• Imaging study of [68Ga]Ga-DWJ155 in adults with solid tumors

  This trial tests a new radioligand imaging agent, [68Ga]Ga-DWJ155, to see how well it images tumors and how safe it is in adults with advanced solid cancers.

  Recruiting at 2 sites Phase 1 Novartis · Darlinghurst, New South Wales and 1 other locations · NCT07801508

• Can older adults with breast cancer tolerate a dense CMF chemo schedule

  This study tests whether giving a condensed CMF chemotherapy regimen is feasible for people 70 and older with breast cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07768436

• Oral paclitaxel in triple-negative breast cancer before main chemotherapy

  This trial tests whether giving an oral paclitaxel dose-6 in combination with standard epirubicin and cyclophosphamide can be tolerated in women with triple-negative breast cancer before surgery.

  Recruiting Phase 1/2 The Affiliated Hospital Of Guizhou Medical University · Guiyang, Guizhou · NCT07739485

• Granzyme B-PET to see if immunotherapy works in TNBC

  This study will test whether a Granzyme B PET/CT scan can help predict how well immunotherapy will work for adults with locally advanced or metastatic triple-negative breast cancer receiving an immune checkpoint inhibitor.

  Recruiting Fudan University · Shanghai · NCT07705438

• Combination therapy for residual triple-negative breast cancer after neoadjuvant treatment

  This Phase 3 trial tests whether Trastuzumab Rezetecan plus Adebrelimab works better than the investigator’s choice in people with residual invasive triple-negative breast cancer after prior treatment.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07679360

• THE-0504 in patients with solid tumors

  A first-in-human, dose-escalation study to see if THE-0504 is safe and tolerable in adults with solid tumors such as SCLC, CRC, GC, TNBC, and pancreatic cancer.

  Recruiting Phase 1 Thena Biotech S.r.l. · Rome, Lazio · NCT07646106

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• JSKN016 versus physician's choice for advanced triple-negative breast cancer after prior treatments

  This trial will test whether JSKN016 works better than a physician's choice chemotherapy for adults with unresectable locally advanced, recurrent, or metastatic triple-negative breast cancer who have already had at least two prior systemic chemotherapies.

  Recruiting Phase 3 Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Guangzhou, Guangdong · NCT07533123

• Pegfilgrastim to prevent fever and low white blood cells during AC chemotherapy after paclitaxel and carboplatin in triple‑negative breast cancer

  This will test whether a single 6 mg pegfilgrastim shot given about 24 hours after each AC chemotherapy cycle can prevent febrile neutropenia in adults with triple‑negative breast cancer who previously received paclitaxel and carboplatin.

  Recruiting at 2 sites Yonsei University · Seoul, Seodaemun-gu and 1 other locations · NCT07525869

• Dual-target CAR-NK therapy for advanced HER2-positive and triple-negative breast cancer

  This trial will test a dual-target CAR-NK cell therapy in adults with advanced HER2-positive or triple-negative breast cancer who have progressed on or cannot receive standard treatments.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07510802

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

• ITC-6146RO in advanced cancers beyond standard therapy

  A new drug called ITC-6146RO is being tested to see if it is safe and can help people with advanced cancers who have no other approved options.

  Recruiting at 3 sites Phase 1 IntoCell, Inc · Seoul, Seoul and 2 other locations · NCT07423117

• Extended-interval versus standard-interval immunotherapy for advanced triple-negative breast cancer

  This trial tests whether giving immunotherapy less often works as well and causes fewer immune-related side effects than the standard schedule for adults with advanced triple-negative breast cancer who responded to initial combination therapy.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07401537

• Dose-modified cancer therapy for people with Duffy null phenotype

  This pilot study tests whether using Duffy null-specific dosing guidelines can reduce dose changes and prevent neutropenic fever in people with Duffy null who are treated for multiple myeloma or triple negative breast cancer.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07341867

• Adaptive biomarker-driven therapies for metastatic breast cancer

  This trial tests whether matching targeted drug combinations to tumor biomarkers helps people with ER+/HER2- or triple-negative metastatic breast cancer who are starting second-line treatment.

  Recruiting at 4 sites Phase 2 UNC Lineberger Comprehensive Cancer Center · New Haven, Connecticut and 5 other locations · NCT07340541

• Tumor-informed ctDNA testing for people with small, early-stage triple-negative breast cancer

  This project will test whether a highly sensitive tumor-informed blood test (ctDNA) can detect tumor DNA in people newly diagnosed with small, stage I triple-negative breast cancer before and during their treatment.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07332975

• New oral medicine PF-08032562 for advanced or metastatic breast and colorectal cancer

  This trial will try an oral medicine called PF-08032562, given alone or with other cancer drugs, in adults with advanced or metastatic breast or colorectal cancer.

  Recruiting at 13 sites Phase 1 Pfizer · Duarte, California and 16 other locations · NCT07318805

• GCAR1 CAR-T therapy for GPNMB-expressing solid tumours

  This study tests different doses of GCAR1 CAR-T cells in people with specific cancers that make high levels of the GPNMB protein to see if the treatment is safe and how it affects the cancer.

  Recruiting at 3 sites Phase 1 Canadian Cancer Trials Group · Calgary, Alberta and 3 other locations · NCT07297667

• Pre-surgery serplulimab with weekly paclitaxel and carboplatin for triple-negative breast cancer

  This trial tests whether adding serplulimab to weekly paclitaxel and carboplatin before surgery helps people with triple-negative breast cancer respond better to treatment.

  Recruiting Phase 2 RenJi Hospital · Shanghai · NCT07283692

• LBL-024 alone or with chemotherapy for recurrent or metastatic triple-negative breast cancer

  This trial tests whether LBL-024 by itself or together with albumin-bound paclitaxel can shrink tumors or slow disease in people with recurrent or metastatic triple-negative breast cancer.

  Recruiting at 7 sites Phase 1/2 Nanjing Leads Biolabs Co.,Ltd · Guangzhou, Guangdong and 6 other locations · NCT07281976

• Targeted radioligand [177Lu]Lu-DFC413 for advanced pancreatic, lung, breast, and colorectal cancers

  This will test a new targeted radioactive medicine, [177Lu]Lu-DFC413 (with a PET tracer [68Ga]Ga-NNS309), to see if it is safe and shows activity in adults with advanced pancreatic, lung, breast, or colorectal cancer.

  Recruiting at 9 sites Phase 1 Novartis · Princeton, New Jersey and 8 other locations · NCT07261631

• Testing AZD6750 safety in adults with selected advanced or metastatic solid tumors

  This trial tests whether AZD6750, a CD8-guided IL-2 medicine given alone or with other cancer drugs, is safe and how it behaves in adults with certain advanced or metastatic solid tumors.

  Recruiting at 13 sites Phase 1/2 AstraZeneca · Grand Rapids, Michigan and 12 other locations · NCT07115043

• BCD-236 plus chemotherapy for relapsed or metastatic triple negative breast cancer

  This trial will try BCD-236 together with chemotherapy to see if it helps people with relapsed or metastatic triple negative breast cancer whose tumors show AXL.

  Recruiting at 40 sites Phase 2 Biocad · Brest and 46 other locations · NCT07108309

• Celecoxib during radiotherapy for early triple-negative breast cancer

  This test gives celecoxib pills during radiotherapy to see if it can stop radiation-triggered cytokine increases and lower the chance of recurrence in adults with early-stage triple-negative breast cancer.

  Recruiting Phase 2 Université de Sherbrooke · Sherbrooke, Quebec · NCT07104266

• Serial multisite image-guided biopsies to track breast cancer evolution

  The team will try taking repeated image-guided biopsies and blood samples from adults with metastatic or advanced breast cancer to see how their tumors change during treatment.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT07084571

• Lifestyle, exercise, and nutrition program to improve response in triple-negative breast cancer

  This will test whether weekly remote nutrition counseling and a home-based exercise program can help women with stage II–III triple-negative breast cancer have no remaining tumor in the breast after chemo-immunotherapy before surgery.

  Recruiting Yale University · New Haven, Connecticut · NCT07066189

• Single-protein encapsulated doxorubicin (SPEDOX-6) for advanced solid tumors

  We will try SPEDOX-6, a protein-encapsulated form of doxorubicin, to find a safe dose and see if it helps adults with advanced, treatment-resistant solid tumors (including certain sarcomas, triple-negative breast cancer, non-small cell lung cancer, cervical, ovarian, and KRAS‑mutant pancreatic cancers) who have not rec

  Recruiting Phase 1/2 University of California, Irvine · Orange, California · NCT07064018

• LY4175408 for selected advanced lung, endometrial, and triple‑negative breast cancers

  This trial tests an experimental drug called LY4175408 to see if it is safe and works for people with advanced or metastatic non‑small cell or small cell lung cancer, endometrial cancer, or triple‑negative breast cancer.

  Recruiting at 24 sites Phase 1 Eli Lilly and Company · Stanford, California and 26 other locations · NCT07046923

• JS207 with 9MW2821 or albumin-bound paclitaxel for recurrent or metastatic triple-negative breast cancer

  This trial will try JS207 together with either 9MW2821 or albumin-bound paclitaxel as first-line treatment for people with recurrent or metastatic triple-negative breast cancer who have not had systemic therapy for their advanced disease.

  Recruiting at 14 sites Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Hefei, Anhui and 21 other locations · NCT07045311

• DR-0202 for advanced, relapsed, or treatment-resistant carcinomas

  This trial tests DR-0202 in adults with advanced or metastatic carcinomas—such as certain breast, lung, cervical, and prostate cancers—that have relapsed or stopped responding to standard treatments.

  Recruiting at 10 sites Phase 1 Dren Bio · Denver, Colorado and 9 other locations · NCT06999187

• Datopotamab deruxtecan with or without durvalumab for PD-L1–negative metastatic triple-negative breast cancer

  This will see if adding durvalumab to datopotamab deruxtecan helps people with PD-L1–negative advanced or metastatic triple-negative breast cancer live longer without their disease getting worse.

  Recruiting Phase 2 Queen Mary University of London · London and 1 other locations · NCT06954480

• Testing a new dosing schedule of sacituzumab govitecan for advanced triple-negative breast cancer

  This study is testing a new way to give a cancer drug called sacituzumab govitecan to see if it is safe and effective for people with advanced triple-negative breast cancer.

  Recruiting at 15 sites Phase 1/2 Gilead Sciences · Los Angeles, California and 15 other locations · NCT06926920

• Using mistletoe extract with pembrolizumab for treating triple negative breast cancer

  This study is testing if adding mistletoe extract to pembrolizumab can help adults with triple negative breast cancer feel better after surgery.

  Recruiting Phase 4 Ilsan Cha hospital · Goyang-si, Gyeonggi-do · NCT06920810

• Dose-randomized bulumtatug fuvedotin for triple-negative breast cancer previously treated with antibody-drug conjugates

  This trial will test whether different doses of bulumtatug fuvedotin can help adults with recurrent or metastatic triple-negative breast cancer who have already received antibody-drug conjugates.

  Recruiting at 6 sites Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Duarte, California and 6 other locations · NCT06908928

• Camrelizumab plus apatinib and eribulin versus physician's choice chemotherapy for advanced triple-negative breast cancer

  This trial tests whether combining camrelizumab, apatinib, and eribulin works better than your doctor's chosen chemotherapy for adults with advanced triple-negative breast cancer who have had 1–4 prior systemic treatments.

  Recruiting at 5 sites Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong and 6 other locations · NCT06889688

• Using imaging and blood tests to predict response to pre-surgery chemo‑immunotherapy in triple‑negative breast cancer

  We will try to see if imaging scans and blood tests can predict which people with triple‑negative breast cancer will have no remaining tumor after pre‑surgery chemo‑immunotherapy.

  Recruiting Centre Henri Becquerel · Rouen · NCT06879704

• Anthracycline-free pre-surgery chemoimmunotherapy for triple-negative breast cancer

  This 12–18 week treatment will test whether carboplatin, paclitaxel, and pembrolizumab before surgery can work for people with stage II–III triple-negative breast cancer who cannot receive anthracyclines because of heart problems.

  Recruiting Phase 2 Medical University of South Carolina · Charleston, South Carolina · NCT06845319

• Combination therapy for early triple-negative breast cancer

  This study is testing a new combination of medications to see if it helps people with early-stage triple-negative breast cancer respond better to treatment before surgery.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT06817525

• Testing ATX-295 for advanced solid tumors and ovarian cancer

  This study is testing a new oral medication called ATX-295 to see if it is safe and effective for people with advanced solid tumors, including ovarian cancer.

  Recruiting at 11 sites Phase 1/2 Accent Therapeutics · Aurora, Colorado and 10 other locations · NCT06799065

• Assessing the role of microbiome in treating triple negative breast cancer

  This study is trying to see if the bacteria in the body can help doctors figure out the best treatments for people with early-stage triple negative breast cancer who are about to start chemotherapy and immune therapy.

  Recruiting University College Cork · Cork, Munster · NCT06709651

• Comparing capecitabine treatments for patients with residual triple negative breast cancer after initial therapy

  This study is testing two different ways of giving capecitabine to people with triple negative breast cancer who didn't fully respond to their initial treatment to see which one works better and has fewer side effects.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06700382

• Tiny, direct injections of PBA-0111 into solid tumors to see local immune and tumor responses

  This study will try tiny, localized injections of PBA-0111 into tumors of adults with head and neck cancer, selected soft-tissue sarcomas, or triple-negative breast cancer to see if it triggers immune activity and tumor cell killing in the tumor microenvironment.

  Recruiting Early Phase 1 Pure Biologics S.A. · Shreveport, Louisiana · NCT06700070

• Reducing chemotherapy for triple negative breast cancer with immunotherapy

  This study is testing whether giving less chemotherapy along with immunotherapy can help people with triple negative breast cancer respond better to treatment.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06692725

• Atezolizumab with cyclophosphamide and vinorelbine for metastatic triple-negative breast cancer

  This trial will test whether adding atezolizumab to the chemotherapy drugs cyclophosphamide and vinorelbine helps people with PD-L1–positive metastatic triple-negative breast cancer who are starting first-line treatment after prior PD-1/PD-L1 therapy.

  Recruiting at 2 sites Phase 2 European Institute of Oncology · Monza, Monza and 4 other locations · NCT06690840

• Evaluating a new CAR T-cell therapy for solid tumors expressing EGFR

  This study is testing a new CAR T-cell therapy to see if it can safely help adults with certain solid tumors, like colorectal and lung cancer, that have specific markers.

  Recruiting at 10 sites Phase 1/2 A2 Biotherapeutics Inc. · Gilbert, Arizona and 9 other locations · NCT06682793

• Understanding breast cancer response during pre-surgery treatment

  This study is trying to see how breast cancer responds to treatment before surgery by looking at tissue and blood samples from patients to find out what factors might affect their recovery and risk of cancer coming back.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT06681064

• Personalized cancer vaccine for treating triple-negative breast cancer

  This study is testing a personalized cancer vaccine for people with triple-negative breast cancer to see if it can improve their treatment results when used with standard therapies.

  Recruiting at 2 sites Phase 1/2 NEC Bio B.V · Erlangen and 1 other locations · NCT06631092

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

• Evaluating PSMA in Metastatic Triple Negative Breast Cancer

  This study is testing if a special imaging technique can help find cancer spots in patients with metastatic triple negative breast cancer to see if new treatments targeting those spots could work.

  Recruiting Early Phase 1 University of Iowa · Iowa City, Iowa · NCT06586047

• Evaluating a new treatment for advanced pancreatic, lung, breast, and colorectal cancers

  This study is testing a new type of radiation treatment for people with advanced pancreatic, lung, breast, and colorectal cancers to see if it is safe and effective.

  Recruiting at 29 sites Phase 1 Novartis · Birmingham, Alabama and 28 other locations · NCT06562192

• MOv18 IgE treatment for platinum-resistant ovarian cancer

  This study is testing a new treatment called MOv18 IgE for people with platinum-resistant ovarian cancer to see if it can help shrink tumors and improve their health.

  Recruiting at 7 sites Phase 1 Epsilogen Ltd · Bristol and 6 other locations · NCT06547840

• Combination of Tislelizumab and Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer with Bone Metastasis

  This study is testing if a new combination of Tislelizumab and Nab-Paclitaxel can effectively treat patients with advanced triple-negative breast cancer that has spread to their bones.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06538896

• Combining PD-1 inhibitors with PARPi or capecitabine for high-risk triple-negative breast cancer

  This study is testing if combining PD-1 inhibitors with either a specific cancer drug or chemotherapy can help people with high-risk triple-negative breast cancer who didn't respond fully to earlier treatment.

  Recruiting Phase 3 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT06533384

• Evaluating 9MW2821 and PD-1 Inhibitor for Advanced Triple-Negative Breast Cancer

  This study is testing a new treatment called 9MW2821, alone or with another drug, to see if it helps people with advanced triple-negative breast cancer feel better.

  Recruiting Phase 2 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT06492005

• Combining BL-B01D1 and PD-1 Antibody for Advanced Triple-negative Breast Cancer

  This study is testing a new combination treatment for people with advanced triple-negative breast cancer to see if it can help shrink their tumors.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06471205

• LY4052031 for advanced or metastatic urothelial and other nectin‑4–expressing solid tumors

  This trial will test whether LY4052031 is safe and can help people with advanced or metastatic urothelial cancer or other solid tumors that express nectin‑4.

  Recruiting at 36 sites Phase 1 Eli Lilly and Company · Duarte, California and 39 other locations · NCT06465069

• Combining ProAgio with Gemcitabine for Metastatic Triple Negative Breast Cancer

  This study is testing if a new treatment combining ProAgio with gemcitabine can help people with metastatic triple negative breast cancer feel better and respond to the treatment.

  Recruiting Phase 1/2 ProDa BioTech, LLC · Atlanta, Georgia and 1 other locations · NCT06460298

• Testing ZM008 alone and with Pembrolizumab in patients with advanced solid tumors

  This study is testing a new treatment called ZM008, alone and with another drug called Pembrolizumab, to see if it can help patients with advanced solid tumors who have run out of other treatment options.

  Recruiting at 3 sites Phase 1 Zumutor Biologics Inc. · Boston, Massachusetts and 2 other locations · NCT06451497

• Personalized vaccine for high-risk triple negative breast cancer after chemotherapy

  This study is testing a personalized vaccine made from a patient's own immune cells to see if it can help people with high-risk triple negative breast cancer fight any leftover cancer after chemotherapy.

  Recruiting Early Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06435351

• Combination treatment for triple-negative breast cancer after surgery

  This study is testing a new combination treatment for people with triple-negative breast cancer who didn't fully respond to earlier therapy after surgery to see if it helps them stay cancer-free longer.

  Recruiting at 299 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 313 other locations · NCT06393374

• Oral all-trans retinoic acid plus toripalimab for advanced or metastatic triple-negative breast cancer

  This test tries whether taking oral all‑trans retinoic acid together with the immunotherapy toripalimab helps people with locally advanced, recurrent, or metastatic triple‑negative breast cancer who have failed at least two prior treatments.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang Province, P.R. China · NCT06371274

• Combining Cadonilimab with chemotherapy for treating advanced triple-negative breast cancer

  This study is testing if combining a new antibody treatment called Cadonilimab with chemotherapy can help people with advanced triple-negative breast cancer feel better compared to standard treatments.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT06367088

• Treatment for early triple-negative breast cancer using INT230-6 and immuno-chemotherapy

  This study is testing a new treatment called INT230-6, combined with chemotherapy, to see if it can help people with early-stage triple-negative breast cancer have better outcomes before surgery.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Lyon and 9 other locations · NCT06358573

• Combination of INBRX-106 and Pembrolizumab for Treating Stage II Triple Negative Breast Cancer

  This study is testing a new combination of two drugs, INBRX-106 and pembrolizumab, to see if it can help people with Stage II Triple Negative Breast Cancer avoid chemotherapy.

  Recruiting at 3 sites Phase 2 Providence Health & Services · Los Angeles, California and 2 other locations · NCT06353997

• Using PET/CT imaging to predict treatment response in triple-negative breast cancer

  This study is testing if a special type of imaging can help predict how well early-stage triple-negative breast cancer patients will respond to their treatment with pembrolizumab and chemotherapy.

  Recruiting at 6 sites Institut Curie · Antony and 5 other locations · NCT06349512

• Treatment using CAR-T cells targeting B7-H3 for triple-negative breast cancer

  This study is testing a new CAR-T cell treatment aimed at a specific target for people with hard-to-treat triple-negative breast cancer to see if it is safe and how much can be given.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06347068

• Using MRI to detect early breast cancer metastases

  This study is testing if a special type of MRI can help find early signs of breast cancer returning in high-risk patients to see if it can improve their chances of living longer.

  Recruiting European Institute of Oncology · Milan · NCT06328465

• Neoadjuvant treatment for early-stage triple negative breast cancer

  This study is testing if a new combination of treatments can help people with early-stage triple negative breast cancer respond better to therapy before surgery.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06318897

• Combination chemotherapy for Nigerian women with triple-negative breast cancer.

  This will test whether epirubicin plus cyclophosphamide followed by docetaxel plus carboplatin leads to complete tumor disappearance at surgery and whether blood biomarkers can show chemotherapy resistance in Nigerian women with triple-negative breast cancer.

  Recruiting at 4 sites Phase 2 University of Chicago · Ikeja, Lagos and 3 other locations · NCT06291064

• Non-surgical treatment for breast cancer after chemotherapy

  This study tests if using radiotherapy alone is a safe and effective option for breast cancer patients who have responded well to chemotherapy, instead of undergoing surgery.

  Recruiting European Institute of Oncology · Candiolo, Turin and 1 other locations · NCT06281210

• Examining LAG3 Expression in Triple Negative Breast Cancer

  This study is testing how a protein called LAG-3 affects treatment outcomes in patients with triple negative breast cancer who are receiving chemotherapy along with an immune therapy.

  Recruiting Samsung Medical Center · Seoul · NCT06259162

• Combining pembrolizumab with cryoablation for metastatic breast cancer

  This study is testing if combining a drug called pembrolizumab with a freezing treatment can help people with advanced triple negative breast cancer feel better compared to just using the drug alone.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06246968

• Using PET scans to guide treatment for triple negative breast cancer

  This study tests if using PET scans can help doctors tailor treatment for people with stage 2 and 3 triple negative breast cancer to improve their chances of a successful surgery.

  Recruiting at 2 sites Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland and 1 other locations · NCT06245889

• Combining Sacituzumab Govitecan and Zimberelimab with Stereotactic Radiation for Metastatic Triple Negative Breast Cancer with Brain Metastases

  This study is testing if combining two treatments, Sacituzumab Govitecan and Zimberelimab, with targeted radiation can help adults with metastatic triple negative breast cancer that has spread to the brain feel better compared to just using Sacituzumab Govitecan alone.

  Recruiting Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06238921

• Early detection of relapse in triple‑negative breast cancer using blood DNA and advanced PET imaging

  This study tests whether regular ctDNA blood checks combined with 68Ga‑FAPI‑46 and 18F‑FDG PET‑CT scans can find relapse earlier in people who finished treatment for high‑risk, non‑metastatic triple‑negative breast cancer.

  Recruiting Institut Curie · Avignon and 12 other locations · NCT06225505

• Neoadjuvant chemotherapy with or without hormone therapy for young women with triple-negative breast cancer

  This study is testing if adding a hormone therapy to standard chemotherapy can help young women with triple-negative breast cancer respond better to treatment.

  Recruiting Phase 2 National Taiwan University Hospital · Taipei · NCT06225284

• ARX788 for HER2-low breast cancer

  This phase 2 study tests ARX788 as a single-drug treatment for adults with HER2-low locally advanced unresectable or metastatic breast cancer.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT06224673

• Using advanced mammography techniques to assess breast cancer treatment response

  This study is testing two new mammography techniques to see if they can better predict how well chemotherapy is working for people with locally advanced breast cancer.

  Recruiting Early Phase 1 Stony Brook University · Stony Brook, New York · NCT06220214

• Testing CTX-8371 in patients with advanced cancers

  This study is testing a new treatment called CTX-8371 in patients with advanced cancers to see if it can help them when other treatments haven't worked.

  Recruiting at 11 sites Phase 1 Compass Therapeutics · Birmingham, Alabama and 11 other locations · NCT06150664

• Combining Tetrathiomolybdate with Capecitabine for Triple Negative Breast Cancer

  This study is testing if adding a new drug called tetrathiomolybdate to the usual treatment for high-risk triple negative breast cancer can help patients who still have cancer after their initial therapy.

  Recruiting at 2 sites Phase 1/2 Dartmouth-Hitchcock Medical Center · Indianapolis, Indiana and 2 other locations · NCT06134375

• Investigating ctDNA in Breast Cancer Treatment

  This study is testing if blood samples can help predict how well neoadjuvant chemotherapy works for women with stage II-III HER2-positive and triple-negative breast cancer.

  Recruiting at 3 sites Gene Solutions · Jakarta and 2 other locations · NCT06087120

• Assessing the effects of ABBV-400 on advanced solid tumors

  This study is testing a new drug called ABBV-400 to see if it can help adults with advanced solid tumors like liver, pancreatic, and triple negative breast cancer feel better and manage their disease.

  Recruiting at 47 sites Phase 1 AbbVie · Duarte, California and 53 other locations · NCT06084481

• Comparing two treatments for low-risk triple-negative breast cancer

  This study is testing whether adding pembrolizumab to sacituzumab govitecan can help people with low-risk triple-negative breast cancer do better after their initial treatment.

  Recruiting at 38 sites Phase 3 Women's Cancer Study Group GmbH · Baden-Baden, Baden-Wurttemberg and 42 other locations · NCT06081244

• Treatment for early-stage triple-negative breast cancer based on tumor lymphocyte infiltration levels

  This study is testing if some patients with early-stage triple-negative breast cancer can safely skip chemotherapy based on their tumor's immune cell levels, to see if it helps them feel better without hurting their chances of recovery.

  Recruiting at 25 sites Phase 2 Unicancer · Amiens and 43 other locations · NCT06078384

• Testing ONM-501 alone and with Cemiplimab for advanced solid tumors and lymphomas

  This study is testing a new treatment called ONM-501, both alone and with another drug called cemiplimab, to see if it can help people with advanced solid tumors and lymphomas who have run out of other treatment options.

  Recruiting at 5 sites Phase 1 OncoNano Medicine, Inc. · Los Angeles, California and 15 other locations · NCT06022029

• Engineered T cells for treating advanced triple negative breast cancer

  This study is testing a new treatment using specially engineered T cells to see if it can help people with advanced triple negative breast cancer that has come back or does not respond to other treatments.

  Recruiting Phase 1 University of Southern California · Los Angeles, California · NCT05989828

• Evaluating BL-B01D1 for patients with advanced lung and solid tumors

  This study is testing a new treatment called BL-B01D1 to see if it is safe and effective for people with advanced lung cancer and other solid tumors.

  Recruiting at 37 sites Phase 1 SystImmune Inc. · Beverly Hills, California and 36 other locations · NCT05983432

• Identifying biomarkers for treatment response in triple negative breast cancer

  This study is testing if certain biological markers in tissue samples can help doctors predict how well treatments will work for people with stage II-III triple negative breast cancer.

  Recruiting Vall d'Hebron Institute of Oncology · Barcelona · NCT05916755

• Combining antivascular therapy with chemotherapy for treating triple-negative breast cancer

  This study is testing if adding a new type of treatment that targets blood vessels to standard chemotherapy can help women with triple-negative breast cancer do better after surgery.

  Recruiting at 15 sites Phase 3 Fudan University · Beijing, Beijing Municipality and 14 other locations · NCT05909332

• Testing VLS-1488 for advanced cancers

  This study is testing a new oral medication called VLS-1488 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 13 sites Phase 1/2 Volastra Therapeutics, Inc. · Los Angeles, California and 13 other locations · NCT05902988

• Platform program for evaluating treatments in metastatic HER2-positive breast cancer

  This study is testing different new treatments for people with advanced HER2-positive breast cancer to see which ones work best before moving them to larger trials.

  Recruiting at 5 sites Phase 1/2 QuantumLeap Healthcare Collaborative · Birmingham, Alabama and 9 other locations · NCT05868226

• Chemotherapy with or without Tocilizumab for certain types of breast cancer

  This study is testing if adding a drug called tocilizumab to standard chemotherapy helps people with certain types of advanced breast cancer feel better compared to just chemotherapy alone.

  Recruiting at 7 sites Phase 2 Indiana University · Atlanta, Georgia and 6 other locations · NCT05846789

• Targeted treatment for a specific subtype of triple-negative breast cancer

  This study is testing a new treatment combining VEGFR BP102 with nab-paclitaxel to see if it works better than standard options for people with a specific type of triple-negative breast cancer who haven't had chemotherapy before.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT05806060

• Combining Famitinib and Camrelizumab for Treating Advanced Triple-Negative Breast Cancer

  This study is testing if combining Famitinib with Camrelizumab can help people with advanced triple-negative breast cancer do better than just using Camrelizumab with another treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT05760378

• Precision therapy for refractory triple-negative breast cancer

  This study is testing personalized treatments for patients with hard-to-treat triple-negative breast cancer to see if targeting their specific cancer type improves their outcomes.

  Recruiting Phase 2 Fudan University · Shanghai · NCT05749588

• Testing NM1F with Pembrolizumab in Patients with Advanced Solid Tumors

  This study is testing a new treatment called NM1F, both alone and with another drug called pembrolizumab, to see if it can help people with advanced solid tumors.

  Recruiting at 2 sites Phase 1 Hefei TG ImmunoPharma Co., Ltd. · Dallas, Texas and 1 other locations · NCT05746897

• Using imatinib to convert triple-negative breast cancer into ER-positive breast cancer

  This gives 10 days of imatinib to people with newly diagnosed triple-negative breast cancer before surgery to see if their tumors become estrogen receptor (ER)–positive.

  Recruiting Vastra Gotaland Region · Gothenburg · NCT05722795

• Combination treatment for triple negative breast cancer after surgery

  This study is testing if a new combination of two cancer drugs can help adults with triple negative breast cancer who still have cancer after surgery feel better and live longer.

  Recruiting at 290 sites Phase 3 Gilead Sciences · Birmingham, Alabama and 377 other locations · NCT05633654

• Testing a new antibody for advanced solid tumors

  This study is testing a new antibody treatment for people with advanced solid tumors that haven't responded to other therapies to see how safe it is and how well it works.

  Recruiting Phase 1 A&G Pharmaceutical Inc. · Baltimore, Maryland · NCT05627960

• Testing Rinatabart Sesutecan for advanced solid tumors

  This study is testing a new drug called Rinatabart Sesutecan to see if it can safely help people with advanced solid tumors, like certain types of ovarian and endometrial cancers.

  Recruiting at 67 sites Phase 1/2 Genmab · Phoenix, Arizona and 66 other locations · NCT05579366

• Using Simvastatin to Improve Treatment for Triple Negative Breast Cancer

  This study is testing if adding simvastatin to chemotherapy can help women with advanced triple-negative breast cancer respond better to treatment.

  Recruiting Phase 2 Universitas Indonesia · Jakarta Pusat, DKI Jakarta · NCT05550415

• Genomically guided radiation therapy for triple negative breast cancer

  This study is testing if personalized radiation therapy based on the genetic makeup of triple negative breast cancer can improve treatment for patients who have had breast-conserving surgery.

  Recruiting at 2 sites Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Clearwater, Florida and 1 other locations · NCT05528133

• DC1 dendritic-cell vaccine with chemotherapy for early-stage triple-negative and ER-low breast cancer

  This trial will test whether a dendritic cell vaccine given with standard chemotherapy helps people with early-stage triple-negative or ER-low breast cancer.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT05504707

• Exploring a new cancer treatment using PeptiCRAd-1 and checkpoint inhibitors

  This study is testing a new cancer treatment that combines a special virus with immune therapy to see if it can help people with advanced cancer who haven't responded to other treatments.

  Recruiting at 2 sites Phase 1 Valo Therapeutics Oy · Frankfurt and 6 other locations · NCT05492682

• Combining ADG106 and pembrolizumab for advanced solid tumors and triple negative breast cancer

  This study is testing if combining two treatments, ADG106 and pembrolizumab, can help people with advanced solid tumors, especially those with triple negative breast cancer, feel better and respond to treatment.

  Recruiting Phase 1/2 National University Hospital, Singapore · Singapore · NCT05491083

• New treatment approach for BRCA1/2 mutated triple negative breast cancer

  This study is testing a new treatment combining Olaparib and Pembrolizumab for people with BRCA1/2 mutated triple negative breast cancer to see if it works better after chemotherapy.

  Recruiting at 3 sites Phase 2 Okayama University · Gifu, Gifu and 2 other locations · NCT05485766

• Combining Camrelizumab with TCb for treating triple-negative breast cancer

  This study is testing if combining a new drug called camrelizumab with a chemotherapy treatment can help people with triple-negative breast cancer do better after surgery.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT05475678

• Combining camrelizumab, apatinib, and chemotherapy for treating triple negative breast cancer

  This study tests if a new combination of camrelizumab, apatinib, and chemotherapy can help shrink tumors and improve outcomes for patients with early or locally advanced triple negative breast cancer before surgery.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT05447702

• Collecting tumor samples from triple-negative breast cancer patients to explore new treatments and biomarkers.

  This study is collecting tumor samples from people with triple-negative breast cancer to see if new treatments and markers can help improve their care.

  Recruiting Centre Francois Baclesse · Caen · NCT05404321

• Testing a new drug called XMT-1660 for solid tumors

  This study is testing a new drug called XMT-1660 to see if it is safe and effective for people with hard-to-treat solid tumors like triple negative breast cancer and ovarian cancer.

  Recruiting at 26 sites Phase 1/2 Day One Biopharmaceuticals, Inc. · Phoenix, Arizona and 25 other locations · NCT05377996

• Modi-1 vaccine for advanced cancers

  This study is testing a new vaccine for people with advanced cancers like triple negative breast cancer and ovarian cancer to see if it can boost their immune response and work better with other treatments.

  Recruiting at 13 sites Phase 1/2 Scancell Ltd · Brighton, Default and 15 other locations · NCT05329532

• Infusion of engineered lymphocytes for patients with NY-ESO-1 expressing metastatic cancers

  This study is testing a new treatment using specially modified immune cells to see if it can help people with certain advanced cancers that have the NY-ESO-1 marker.

  Recruiting Phase 1/2 Hadassah Medical Organization · Jerusalem · NCT05296564

• Combining albumin-bound paclitaxel with antiangiogenic agents for treating relapsed or metastatic triple-negative breast cancer

  This study is testing whether combining a specific cancer drug with two different treatments can help women with advanced triple-negative breast cancer live longer without their cancer getting worse.

  Recruiting Phase 2 The First Affiliated Hospital of Bengbu Medical University · Bengbu, Anhui · NCT05192798

• Screening brain MRIs for patients with stage IV breast cancer

  This study tests if regular brain MRI scans can help find hidden issues in the brains of patients with stage IV breast cancer who don’t have any symptoms yet.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Clearwater, Florida and 1 other locations · NCT05115474

• Oncolytic virus treatment combined with nivolumab for advanced solid tumors

  This study is testing a new virus treatment combined with an existing cancer drug to see if it can help people with advanced solid tumors, like lung cancer, whose cancer has not improved with previous treatments.

  Recruiting Phase 1 Memgen, Inc. · Tampa, Florida and 1 other locations · NCT05076760

• Reversing immune resistance in triple-negative breast cancer

  This Phase II will test whether adding several drugs (like choline, sodium cromoglicate, efavirenz, SHR compounds, and theophylline) to an anti–PD‑1 treatment can overcome resistance in people with metastatic triple‑negative breast cancer that progressed after prior immunotherapy.

  Recruiting Phase 2 Fudan University · Shanghai · NCT05076682

• Exploring the gut microbiome's role in cancer treatment response

  This study is testing how the bacteria in the gut might affect how well cancer patients respond to a specific type of treatment called immune checkpoint inhibitors.

  Recruiting VastBiome · Elizabethtown, Kentucky · NCT05037825

• Understanding how tumor shrinkage predicts cancer response in early breast cancer patients

  This study tests if measuring how much breast tumors shrink during chemotherapy can help predict how well the treatment will work for women with early-stage breast cancer.

  Recruiting at 2 sites Phase 2 Baylor Breast Care Center · Houston, Texas and 1 other locations · NCT05020860

• Assessing the safety and effects of Azirkitug in cancer patients

  This study is testing a new cancer drug called Azirkitug to see how safe it is and how well it works for adults with certain types of lung and head and neck cancers.

  Recruiting at 47 sites Phase 1 AbbVie · Duarte, California and 47 other locations · NCT05005403

• Combining seviteronel with chemotherapy for treating a specific type of breast cancer

  This study is testing if combining a new drug called seviteronel with chemotherapy can help people with a tough type of breast cancer feel better and have more treatment options.

  Recruiting Phase 1/2 St Vincent's Hospital, Sydney · Darlinghurst, New South Wales · NCT04947189

• Using advanced PET/MRI with 18F‑FMISO to monitor immunotherapy for triple negative breast cancer

  This project will test whether a special PET/MRI scan with 18F‑FMISO can show and help predict how immunotherapy is working in people with PD‑L1 positive triple negative breast cancer.

  Recruiting Early Phase 1 University of Alabama at Birmingham · Birmingham, Alabama · NCT04861077

• Huaier Granule for treating high-risk early-stage triple-negative breast cancer

  This study is testing if adding Huaier Granule to standard treatment can help people with high-risk early-stage triple-negative breast cancer live longer and feel better.

  Recruiting at 34 sites Phase 4 Fudan University · Hefei, Anhui and 33 other locations · NCT04790305

• Evaluating the safety and effectiveness of ST-067 in treating various solid tumors

  This study is testing a new treatment called ST-067 to see if it can help people with tough-to-treat solid tumors feel better and improve their health.

  Recruiting at 6 sites Phase 1/2 Simcha IL-18, Inc. · Scottsdale, Arizona and 5 other locations · NCT04787042

• MicroRNA and circulating tumor DNA monitoring during chemotherapy for triple negative breast cancer

  This trial will test whether changes in blood microRNA and circulating tumor DNA can show early chemotherapy failure in women with triple negative breast cancer receiving epirubicin–cyclophosphamide followed by paclitaxel–carboplatin.

  Recruiting Phase 2 University College Hospital, Ibadan · Ile-Ife, Oshun and 3 other locations · NCT04771871

• Monitoring tumor DNA in blood during capecitabine treatment for early triple-negative breast cancer

  This study is testing if a blood test that looks for tumor DNA can help find out if people with early triple-negative breast cancer will benefit from capecitabine treatment.

  Recruiting Phase 2 Stanford University · Stanford, California · NCT04768426

• Combining standard chemotherapy with moxifloxacin for treating metastatic triple-negative breast cancer

  This study is testing if adding moxifloxacin to standard chemotherapy can help people with metastatic triple-negative breast cancer live longer without their cancer getting worse.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT04722978

• Combining radiation therapy with pembrolizumab and olaparib for certain breast cancers

  This study tests if adding pembrolizumab, with or without olaparib, to standard radiation therapy can help women with advanced breast cancer feel better compared to just radiation therapy alone.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT04683679

• Vitamin D supplementation for patients with triple negative breast cancer

  This study is testing if giving vitamin D to patients with triple negative breast cancer who are low in vitamin D can help them respond better to chemotherapy compared to those who have enough vitamin D.

  Recruiting Phase 2 Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT04677816

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• Collection of tumor samples from cancer patients for diagnostic test development

  This study is collecting tumor samples from cancer patients who are getting certain treatments to help create better tests for managing cancer in the future.

  Recruiting Cofactor Genomics, Inc. · San Francisco, California · NCT04510129

• Using ctDNA to guide therapy after surgery in triple-negative breast cancer

  This study is testing if using a blood test to find leftover cancer DNA after surgery can help doctors choose better treatments for people with triple-negative breast cancer who are at risk of relapse.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guandong, Guangdong · NCT04501523

• Testing Sacituzumab Govitecan with or without Pembrolizumab for metastatic triple-negative breast cancer

  This study is testing whether a new cancer drug called Sacituzumab Govitecan, alone or with another drug called Pembrolizumab, can help people with metastatic triple-negative breast cancer that hasn't been treated before.

  Recruiting at 15 sites Phase 2 Dana-Farber Cancer Institute · Stamford, Connecticut and 14 other locations · NCT04468061

• Chemotherapy for Triple Negative Breast Cancer Patients with Residual Disease

  This study is testing if giving extra chemotherapy to women with triple negative breast cancer who still have cancer after initial treatment can help them do better than just watching and waiting.

  Recruiting Phase 2 ChineseAMS · Beijing, Beijing Municipality · NCT04437160

• Atezolizumab and sacituzumab govitecan to prevent recurrence in triple-negative breast cancer

  This trial tests whether combining sacituzumab govitecan with atezolizumab can prevent cancer from coming back in people with triple-negative breast cancer who have residual disease after pre-surgery chemotherapy and detectable circulating tumor DNA.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · San Francisco, California and 6 other locations · NCT04434040

• Evaluating sacituzumab govitecan for localized triple negative breast cancer

  This study is testing a new drug called sacituzumab govitecan for people with localized triple negative breast cancer to see if it can help them.

  Recruiting at 4 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 4 other locations · NCT04230109

• Comparing two nab‑paclitaxel combinations for advanced triple‑negative breast cancer

  This test compares nab‑paclitaxel with carboplatin versus nab‑paclitaxel with capecitabine in people with advanced triple‑negative breast cancer who have had up to one prior systemic treatment.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT04159142

• Nab-paclitaxel with carboplatin versus nab-paclitaxel with epirubicin before surgery for triple-negative breast cancer

  This trial will test whether adding carboplatin or adding epirubicin to nab-paclitaxel before surgery works better for women with triple-negative breast cancer.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT04138719

• Effect of Stereotactic Body Radiotherapy on Metastatic Cancer Treatment

  This study tests if combining a targeted type of radiation therapy with regular treatment can help people with metastatic cancer, like triple negative breast cancer and non-small cell lung cancer, live longer before their disease gets worse.

  Recruiting at 11 sites Phase 2 Memorial Sloan Kettering Cancer Center · San Carlos, California and 11 other locations · NCT03808337

• Evaluating a new formulation of Docetaxel for treating triple negative breast cancer

  This study is testing a new version of a breast cancer drug called Docetaxel to see if it works better and is safer for people with triple-negative breast cancer compared to the standard treatment.

  Recruiting at 4 sites Phase 3 Jina Pharmaceuticals Inc. · Columbus, Georgia and 3 other locations · NCT03671044

• Biobanking study to understand cancer and immune response

  This study is collecting tumor and blood samples from cancer patients to see how their tumors and immune responses change during treatment.

  Recruiting at 5 sites Institut Curie · Bordeaux and 5 other locations · NCT03017573

NIH-funded research (newest 40 of 244)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry

  This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.

  NIH research Tuskegee University · Tuskegee Institute, United States · NIH-11621786

• Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans

  A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.

  NIH research Baltimore VA Medical Center · Baltimore, United States · NIH-11608792

• Linking heavy metal exposure to a tougher breast cancer type (TNBC)

  Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.

  NIH research University of Louisville · Louisville, United States · NIH-11567535

• Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate

  Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.

  NIH research Massachusetts Institute of Technology · Cambridge, United States · NIH-11531542

• Rac-enhanced CAR-Macrophages against TNBC

  A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.

  NIH research University of Louisville · Louisville, United States · NIH-11520503

• A new peptide therapy to help treat metastatic triple-negative breast cancer

  A new peptide therapy called PEG-FUD is being tested to help treat metastatic triple-negative breast cancer by normalizing the tumor environment to improve treatment delivery.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11453153

• Photoacoustic imaging to tailor antibody-drug therapy for TNBC

  A non-invasive imaging approach using light-based sound waves (photoacoustic imaging) is being developed to guide and personalize antibody-drug conjugate therapy for women with triple-negative breast cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11445261

• FABP5: How fats in obesity may drive triple negative breast cancer

  A study exploring how a fat‑binding protein called FABP5 helps obesity-related fats push the spread of aggressive breast cancer in models that resemble human disease.

  NIH research University of Iowa · Iowa City, United States · NIH-11444397

• Targeting stress hormone receptor signaling in triple-negative breast cancer

  This project looks at how stress hormone receptors together with HIFs influence aggressive triple-negative breast cancer and whether these interactions could reveal new ways to treat it.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11430882

• Microbial therapies to fight triple-negative breast cancer

  A program aims to create engineered microbes that deliver cancer-fighting therapies directly to TNBC tumors to provoke lasting immune responses.

  NIH research University of Massachusetts Amherst · Hadley, United States · NIH-11422181

• Stable, ultra-tight peptides to block EphB4 and stop TNBC spread

  A new peptide-based approach aims to block a cancer molecule called EphB4 to prevent metastasis in triple-negative breast cancer, especially in African American women.

  NIH research Texas Southern University · Houston, United States · NIH-11420423

• Capecitabine in tough breast cancer with a wearable electric field device

  A new wearable, washable garment delivers a gentle electric field to help treat triple-negative breast cancer in patients who have already tried standard therapies.

  NIH research Embiosys INC. · North Andover, UNITED STATES · NIH-11418087

• Robust mitotic organization in triple-negative breast cancer

  This project studies how chromosome instability in triple-negative breast cancer happens when a key mitotic complex misbehaves, with the goal of finding ways to restore stability and prevent cancer progression.

  NIH research University of Virginia · Charlottesville, United States · NIH-11418076

• Determinants of Response to DNA-Damaging Radiation and Immunotherapy in Triple-Negative Breast Cancer

  This grant explores why some people with triple-negative breast cancer respond to a combo of radiation, chemotherapy, and immunotherapy and why others don’t, to guide more personalized treatment.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11411395

• Understanding how brain metastasis in triple-negative breast cancer is shaped by tumor-immune interactions

  A patient-focused program aims to learn why TNBC spreads to the brain and how the immune system interacts with those cancer cells, with a focus on women of African ancestry.

  NIH research University of California at Davis · Davis, United States · NIH-11411191

• Label-Free Optical Redox Imaging to Predict Outcomes in Early-Stage Triple-Negative Breast Cancer

  A new imaging approach uses intrinsic signals to spot metabolic differences in untreated early-stage TNBC tumors to help predict how the cancer may behave.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11402679

• Stable, potent peptide drug conjugate for treating triple-negative breast cancer

  A new peptide-based drug conjugate is being developed to target hard-to-treat triple-negative breast cancer in patients who may benefit from targeted cytotoxic therapy.

  NIH research Oncotherapy Solutions, LLC · Seattle, UNITED STATES · NIH-11402095

• New immunotherapy combo for hard-to-treat triple-negative breast cancer

  Aims to test a combination immunotherapy with JNK inhibitors to improve treatment for people with triple-negative breast cancer.

  NIH research University of Hawaii at Manoa · Honolulu, United States · NIH-11401949

• Dissecting how TNBC tumors suppress the immune system using myeloid cells

  This NIH grant explores how a protein called TAZ helps triple-negative breast cancer evade the immune system, with the goal of improving treatments for patients with this aggressive cancer.

  NIH research University of Toledo Health Sci Campus · Toledo, United States · NIH-11398169

• Understanding how BACH1 controls lactate use in triple-negative breast cancer

  A research project aims to see how turning off BACH1 changes how cancer cells in triple-negative breast cancer use lactate, with the goal of making therapies targeting metabolism work better.

  NIH research George Washington University · Washington, United States · NIH-11393880

• Shark-Derived Therapy to Target TNBC with Radioactive Treatment

  A new treatment approach uses shark-derived molecules attached to radioactive therapy to target and kill triple-negative breast cancer cells.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11391249

• Targeted MDM2 Degraders for Better Triple-Negative Breast Cancer Therapy

  A new option for people with triple-negative breast cancer (TNBC) aims to degrade the MDM2 protein to improve treatment outcomes.

  NIH research University of Tennessee Health Sci Ctr · Memphis, United States · NIH-11385538

• Reprogrammed exosome immunotherapy for triple-negative breast cancer

  A new treatment approach uses engineered exosomes to stimulate the immune system to fight triple-negative breast cancer in patients.

  NIH research University of Southern California · Los Angeles, UNITED STATES · NIH-11384983

• Targeting how mechanical stress drives EMT and immune suppression in triple-negative breast cancer

  A Mayo Clinic-led study aims to understand how physical forces in the tumor environment push triple-negative breast cancer cells to become more invasive and less visible to the immune system, with goals to find new ways to stop this resistance.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11384665

• Understanding how high triglycerides may fuel certain breast cancers

  High triglycerides may help triple negative breast cancer grow and spread, and this study looks at how that could happen in patients and models.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11384586

• PRMT inhibitors as a new approach for ovarian and breast cancer

  A cancer research project tests whether drugs that block arginine methylation can help treat high-grade serous ovarian cancer and triple-negative breast cancer.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11383146

• S100A7’s role in metastatic triple-negative breast cancer among African American women

  A new study at Ohio State University aims to understand why triple-negative breast cancer is more aggressive in African American women by looking at how the immune system within tumors may be helping the cancer grow.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11379088

• Immune-suppressing role of Fas/CD95 in triple-negative breast cancer

  A patient-friendly look at a project studying how a cell-surface protein called Fas/CD95 may help or hinder immune responses in triple-negative breast cancer.

  NIH research Northwestern University · Chicago, United States · NIH-11378368

• Antibody-drug conjugates to fight diverse triple-negative breast cancer

  A patient-focused look at a project aiming to use antibody-drug conjugates to tackle diverse triple-negative breast cancers and overcome treatment resistance.

  NIH research University of Texas Hlth Sci Ctr Houston · Houston, United States · NIH-11377479

• Targeting LY6K with NSC243928 to boost immune response in TNBC

  A cancer-focused study aims to find a new way to help people with triple negative breast cancer by using a small molecule that may boost the body’s immune attack on tumors.

  NIH research Henry M. Jackson Fdn for the Adv Mil/med · Bethesda, United States · NIH-11376198

• CB-202: a new drug that blocks MCT4 to target triple-negative breast cancer and some leukemias

  This project is developing a drug called CB-202 that blocks a cancer protein (MCT4) to try to slow triple-negative breast cancer and certain acute myeloid leukemias.

  NIH research Charles R. Drew University of Med & Sci · Los Angeles, United States · NIH-11375952

• Small molecules to block RuvBL1/2 to treat triple-negative breast cancer

  A new drug candidate is being developed to block a protein complex (RuvBL1/2) that TNBC cells rely on to repair DNA, with the goal of helping treat this aggressive breast cancer.

  NIH research Oregon Health & Science University · Portland, United States · NIH-11374910

• Macrocyclic diterpenoids target specific TNBC subtypes

  A new research effort tests natural compounds that may kill certain forms of triple-negative breast cancer more effectively than standard chemotherapy.

  NIH research University of the Incarnate Word · San Antonio, United States · NIH-11373043

• Decoding how chemo and immunity work together in metastatic triple-negative breast cancer

  A research team at the University of Florida is exploring how different chemo drugs combined with PD-1 blockade can best help people with metastatic triple-negative breast cancer.

  NIH research University of Florida · Gainesville, United States · NIH-11373011

• Integrating low-cost paper tests with targeted immunotherapy for triple negative breast cancer

  A research project combines affordable paper-based devices with personalized immune-based treatments to help people with triple negative breast cancer.

  NIH research Delaware State University · Dover, United States · NIH-11368459

• Nurse-led Coping and Support for TNBC patients moving to survivorship

  A nurse-led program called TRANSITIONS helps women with triple-negative breast cancer manage distress and fear as they enter surveillance after curative treatment.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11365935

• Targeting Redox Vulnerabilities in TNBC Stem Cells

  A new approach aims to kill stubborn cancer stem-like cells in triple-negative breast cancer by using a redox-active compound to increase damaging oxygen species, potentially improving outcomes for patients with this aggressive cancer.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11364169

• Stress-related hormonal signals and immune response in a specific breast cancer type

  A study in triple-negative breast cancer looks at how stress hormones may weaken the body's immune attack and whether blocking those signals could improve cancer treatment.

  NIH research Emory University · Atlanta, United States · NIH-11360686

• Molecular drivers of cell fusion in triple negative breast cancer

  A small NIH grant is exploring which genes, when turned on, help TNBC cancer cells fuse and become more abnormal, with the goal of understanding how this affects cancer spread and treatment resistance.

  NIH research University of Texas at Austin · Austin, United States · NIH-11359786

• Improving outcomes for people with a specific type of breast cancer that affects younger women

  A cancer research grant aims to test a targeted AR-blocking treatment combined with standard therapy for a high-AR subset of triple-negative breast cancer to see if it improves outcomes.

  NIH research Vanderbilt University Medical Center · Nashville, United States · NIH-11343444

Related topics

Quick answers

How many Triple Negative Breast Cancer clinical trials are recruiting right now?

142, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 42 countries. The most sites are in United States (67 trials), China (39 trials), France (16 trials), South Korea (15 trials), Spain (12 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 47, Phase 1: 30, Phase 1/2: 22, Phase 3: 12. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →